{"id":390892,"date":"2017-10-04T00:00:00","date_gmt":"2017-10-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0014-2017-biopharma-malignant-melanoma-unmet-need-braf-mutation-positive-unresectable-or-metastatic-us-eu-2017\/"},"modified":"2026-04-21T11:27:26","modified_gmt":"2026-04-21T11:27:26","slug":"unneon0014-2017-biopharma-malignant-melanoma-unmet-need-braf-mutation-positive-unresectable-or-metastatic-us-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0014-2017-biopharma-malignant-melanoma-unmet-need-braf-mutation-positive-unresectable-or-metastatic-us-eu-2017\/","title":{"rendered":"Malignant Melanoma | Unmet Need | BRAF-mutation-positive Unresectable or Metastatic | US\/EU | 2017"},"content":{"rendered":"<p>Treatment of <em><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr><\/em>-mutation-positive unresectable or metastatic malignant melanoma has been transformed in recent years by the identification of <em><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolg B1\">BRAF<\/abbr><\/em>mutations and the development of <abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolg B1\">BRAF<\/abbr> and <abbr title=\"mitogen-activated protein kinase kinase\">MEK<\/abbr> inhibitors, as well as by establishing the disease\u2019s immunogenic properties and subsequent immunotherapy advances. Despite the remarkable <abbr title=\"overall survival\">OS<\/abbr> and <abbr title=\"progression-free survival\">PFS<\/abbr> data demonstrated by some of the new therapies, the prevailing unmet needs in the treatment of <em>BRAF<\/em>-mutation-positive unresectable or metastatic malignant melanoma focus on further improvements in\u00a0<abbr title=\"overall survival\">OS<\/abbr> and <abbr title=\"progression-free survival\">PFS<\/abbr> against current therapies, which continue to be sought by physicians and regulatory authorities alike. Other key efficacy challenges are to overcome the relatively low <abbr title=\"objective response rate\">ORR<\/abbr> associated with immunotherapies and to overcome the relatively short <abbr title=\"duration of response\">DoR<\/abbr> associated with <abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolg B1\">BRAF<\/abbr> and <abbr title=\"mitogen-activated protein kinase kinase\">MEK<\/abbr> inhibitors. Minimizing the incidence of treatment-related toxicities, particularly the incidence of immune-related <abbr title=\"adverse event\">AE<\/abbr>s, is another important unmet need in <em><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr><\/em>-mutation-positive unresectable or metastatic malignant melanoma.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for <em>BRAF<\/em>-mutation-positive unresectable or metastatic malignant melanoma?<\/li>\n<li>What attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for <em>BRAF<\/em>-mutation-positive unresectable or metastatic malignant melanoma?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <em>BRAF<\/em>-mutation-positive unresectable or metastatic malignant melanoma?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new <em>BRAF<\/em>-mutation-positive unresectable or metastatic malignant melanoma drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European medical oncologists fielded in January 2017.<\/p>\n<p><strong>Key companies:<\/strong> Bristol-Myers Squibb, Novartis, Merck<\/p>\n<p><strong>Key drugs:<\/strong> Opdivo, Yervoy, Tafinlar<\/p>\n","protected":false},"template":"","class_list":["post-390892","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390892\/revisions"}],"predecessor-version":[{"id":394016,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390892\/revisions\/394016"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}